Alembic Pharmaceuticals Intrinsic Value
Alembic Pharmaceuticals (APLLTD) median intrinsic value is ₹1161.99 from 9 valuation models (range ₹264–₹1929), vs current price ₹771.50 — +50.6% upside (Trading Below Calculated Value), margin of safety 33.6%. Also explore APLLTD share price history to track price trends across different timeframes.
APLLTD Valuation Methods Summary — DCF, Graham Number & P/E
Alembic Pharmaceuticals intrinsic value across 9 models vs current price ₹771.50 — upside/downside and value range per method. Browse Alembic Pharmaceuticals financial data for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹907.28 | ₹725.82 - ₹1088.74 | +17.6% | EPS: ₹41.24, Sector P/E: 22x |
| Book Value Method | asset | ₹1928.75 | ₹1735.88 - ₹2121.62 | +150.0% | Book Value/Share: ₹1455.13, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1543.00 | ₹1388.70 - ₹1697.30 | +100.0% | Revenue/Share: ₹1922.05, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹1543.00 | ₹1388.70 - ₹1697.30 | +100.0% | EBITDA: ₹920.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹308.60 | ₹246.88 - ₹370.32 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹263.94 | ₹237.55 - ₹290.33 | -65.8% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹637.16 | ₹573.44 - ₹700.88 | -17.4% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹1543.00 | ₹1388.70 - ₹1697.30 | +100.0% | ROE: 14.2%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹1161.99 | ₹1045.79 - ₹1278.19 | +50.6% | EPS: ₹41.24, BVPS: ₹1455.13 |
APLLTD Intrinsic Value vs Market Price — All Valuation Models
Alembic Pharmaceuticals fair value range ₹264–₹1929 vs current market price ₹771.50 across 9 valuation models. For current market price and key ratios, visit Alembic Pharmaceuticals screener.
APLLTD Intrinsic Value Analysis — Undervalued or Overvalued?
Alembic Pharmaceuticals median intrinsic value ₹1161.99, current price ₹771.50 — Trading Below Calculated Value by 50.6%, margin of safety 33.6%.
What is the intrinsic value of APLLTD?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Alembic Pharmaceuticals (APLLTD) is ₹1161.99 (median value). With the current market price of ₹771.50, this represents a +50.6% variance from our estimated fair value.
The valuation range spans from ₹263.94 to ₹1928.75, indicating ₹263.94 - ₹1928.75.
Is APLLTD undervalued or overvalued?
Based on our multi-method analysis, Alembic Pharmaceuticals (APLLTD) appears to be trading below calculated value by approximately 50.6%.
APLLTD Financial Health — Key Ratios vs Industry Benchmarks
Alembic Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.15 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 14.2% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 11.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.86x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
APLLTD Cash Flow Quality — Operating & Free Cash Flow
Alembic Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹88 Cr | ₹-196 Cr | Positive Operating Cash Flow | 6/10 |
| March 2024 | ₹803 Cr | ₹643 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹724 Cr | ₹500 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹552 Cr | ₹366 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1,463 Cr | ₹1,043 Cr | Positive Free Cash Flow | 8/10 |